P1103: INMIND: A PHASE 3 STUDY OF TAFASITAMAB PLUS LENALIDOMIDE AND RITUXIMAB VERSUS PLACEBO PLUS LENALIDOMIDE AND RITUXIMAB FOR RELAPSED/REFRACTORY FOLLICULAR LYMPHOMA (FL) OR MARGINAL ZONE LYMPHOMA (MZL)

Saved in:
Bibliographic Details
Published inHemaSphere Vol. 6; pp. 993 - 994
Main Authors Sehn, L. H., Hübel, K., Luminari, S., Salar, A., Wahlin, B. E., Gopal, A. K., Bonnet, C., Paneesha, S., Trneny, M., Mashegu, H., Lihou, C., Li, D., Scholz, C. W.
Format Journal Article
LanguageEnglish
Published Philadelphia, PA Lippincott Williams & Wilkins 01.06.2022
Online AccessGet full text

Cover

More Information
ISSN:2572-9241
2572-9241
DOI:10.1097/01.HS9.0000847280.69256.81